Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms

Lung neuroendocrine neoplasms (NEN) are a heterogeneous population of neoplasms with different pathology, clinical behavior, and prognosis compared to the more common lung cancers. The diagnostic work-up and treatment of patients with lung- NEN has undergone major recent advances and new methods are currently being introduced into the clinic. These Nordic guidelines summarize and update the Nordic Neuroendocrine Tumor Group's current view on how to diagnose and treat lung NEN-patients and are meant to be useful in the daily practice for clinicians handling these patients. This review reflects our view of the current state of the art of diagnosis and treatment of patients with lung-NEN. Small cell lung carcinoma (SCLC) is not included in these guidelines.

Automated summary

Lung neuroendocrine neoplasms (NEN) are a heterogeneous group of tumors different from common lung cancers in terms of pathology, clinical behavior, and prognosis. Recent advances and new methods in diagnosis and treatment of lung-NEN patients are summarized in these Nordic guidelines. These guidelines are designed to be useful for clinicians in their daily practice and reflect the current state of the art. Small cell lung carcinoma (SCLC) is not covered in these guidelines.